Direct Medical Costs and Healthcare Resource Utilization of Treating Patients With Two Clinical Subtypes of Axial Spondyloarthritis in Colombia

Santos-Moreno, P.; Padilla, D. Parra; Rosa, Fernando Gómez-De la; Carrasquilla-Sotomayor, M; Villarreal, L.; Jervis-Jálabe, D.; Alvis-Zakzuk, Nelson J.

doi:10.1016/j.vhri.2022.08.003

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The economic burden of axSpA per AS patient per year ranges from EUR 5190 in Germany [ 21 ] to USD 23,183.56 in Brazil [ 18 ]. Moreover, data from Poland has shown an increase in healthcare expenses related to AS in recent years—from USD 6.3 million in 2008 to USD 21,900 million in 2013, which might be partly related to the increased number of patients who are treated with biological therapies [ 22 , 23 ] or to increasing availability and utilization of MRI as a diagnostic tool in SpA [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review

Nagit,

Rezus,

Cianga

2024

IJMS

View full text Add to dashboard Cite

Spondylarthritis (SpA) is a chronic inflammatory condition that encompasses damage to the axial or peripheral skeleton, accompanied by specific extra-articular symptoms. Within this group, Ankylosing Spondylitis stands out as the hallmark member. Although the heritability of Ankylosing Spondylitis is estimated to be over 95%, only a portion of the heritability has been explained, with HLA-B27 accounting for 20.1% of it; therefore, ongoing research endeavors are currently concentrated on investigating the potential participation of different entities in the development of the disease. Genome-wide association studies have led to significant advances in our understanding of the genetics of SpA. In this descriptive review, we delve into the pathogenesis of Spondylarthritis beyond HLA-B27. We summarize the latest research on the potential participation of various entities in the development of the disease, including other genetic loci, immune dysregulation, microbiota, and environmental factors. The multifactorial nature of SpA and the complex interplay of genetic, immunological, and environmental factors are being increasingly recognized; therefore, it is of paramount importance to consider a holistic approach to comprehend the pathogenesis of SpA in order to identify novel therapeutic targets.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review

Nagit,

Rezus,

Cianga

2024

IJMS

View full text Add to dashboard Cite

show abstract

Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS)

Garrido-Cumbrera,

Poddubnyy,

Sommerfleck

et al. 2024

Rheumatol Ther

View full text Add to dashboard Cite

Introduction To assess differences in the diagnosis journey and access to care in a large sample of patients with axial spondyloarthritis (axSpA) from around the world, included in the International Map of Axial Spondyloarthritis (IMAS). Methods IMAS was a cross-sectional online survey (2017–2022) of 5557 unselected patients with axSpA from 27 countries. Across five worldwide geographic regions, the patient journey until diagnosis and healthcare utilization in the last 12 months prior to survey were evaluated. Univariable and multivariable linear regression was used to analyze factors associated with higher healthcare utilization. Results Of 5557 participants in IMAS, the diagnosis took an average of 7.4 years, requiring more than two visits to HCPs (77.7% general practitioner and 51.3% rheumatologist), and more than two diagnostic tests [67.5% performed human leukocyte antigen B27 (HLA-B27), 64.2% x-ray, and 59.1% magnetic resonance imaging (MRI) scans]. North America and Europe were the regions with the highest number of healthcare professional (HCP) visits for diagnosis, while the lowest number of visits was in the Asian region. In the previous 12 months, 94.9% ( n = 5272) used at least one healthcare resource, with an average of 29 uses per year. The regions with the highest healthcare utilization were Latin America, Europe, and North America. In the multiple linear regression, factors associated with higher number of healthcare utilization were younger age (b = – 0.311), female gender (b = 7.736), higher disease activity (b = 1.461), poorer mental health (b = 0.624), greater functional limitation (b = 0.300), greater spinal stiffness (b = 1.527), and longer diagnostic delay (b = 0.104). Conclusion The diagnosis of axSpA usually takes more than two visits to HCPs and at least 7 years. After diagnosis, axSpA is associated with frequent healthcare resource use. Younger age, female gender, higher disease activity, poorer mental health, greater functional limitation, greater spinal stiffness, and longer diagnostic delay are associated with higher healthcare utilization. Europe and North America use more HCP visits and diagnostic tests before and after diagnosis than the other regions.

show abstract

Direct Medical Costs and Healthcare Resource Utilization of Treating Patients With Two Clinical Subtypes of Axial Spondyloarthritis in Colombia

Cited by 2 publications

References 25 publications

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review

Exploring the Pathogenesis of Spondylarthritis beyond HLA-B27: A Descriptive Review

Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS)

Contact Info

Product

Resources

About